Subscribe

DOI:

Discover the new country in the Valve for Life initiative, Portugal.

Discover the new country in the Valve for Life initiative, Portugal.

Keep up to date on what has been achieved so far, the challenges and expectations for 2017

Rui Campante Teles, APIC President

The Portuguese population is one of the oldest in Europe. Currently, there are around one million individuals over the age of 75. Around 3.4% of this population present with severe aortic stenosis, with about 75% being symptomatic. It is estimated that in 2015 only about 19% of potential beneficiaries actually received TAVI, and the TAVI/AVR ratio is as low as 1:6 compared to several other European countries which have already reached rates of 1:1.

There were 27 catheterisation laboratories in Portugal in 2016 with 95% of the TAVI activity performed in public hospitals. Most centres with fully operational catheterisation laboratories are part of the public health system and are thus financed by the yearly state budget for healthcare.

After the launch of the Valve for Life initiative in 2015 in Poland and France, it was decided to extend the initiative to Portugal at the beginning of 2017 under the umbrella of the Portuguese Society of Cardiology. The Oversight Committee of the initiative is confident that it can promote the use of this technology in Portugal, increasing the number of TAVI procedures. The efforts of this initiative seem promising and the prospect of duplicating the success of the other participating countries seems realistic.

In Portugal, one of the first objectives of the initiative will be to raise public awareness of the symptoms of valvular heart disease and aortic stenosis while underlining the benefits of currently available treatments. This will allow an increase in the diagnosis of the disease, eventually helping to improve access to treatment. At the same time, it will ensure hospital and cathlab capacity and funding while increasing research and analysis of scientific evidence, including clinical studies for approaches to sedation. A variety of surveys will be undertaken along with a public media campaign. Educational and other meetings and events will be planned. We are also in contact with the Portuguese Medical Association and engaged in meeting with the relevant state health officials.

Rui Campante Teles, FESC

President, APIC- Associação Portuguesa de Intervenção Cardiovascular

VFL Champions: Lino Patrício and Rui Campante Teles

Contact details: APIC - Associação Portuguesa de Intervenção Cardiovascular, Campo Grande 28, 13º, 1700-093 Lisboa, Portugal

E-mail: [email protected]

Webpage: www.valveforlife.pt

NEWS

The spotlight for the ESC Congress 2017 is on “40 years of PCI”! Young clinicians can submit their clinical cases by 1 March 2017 with the late-breaking science submissions open early March. Check it out!

Join the EAPCI Young LinkedIn group: boost your network and stay informed on educational opportunities all year long!

Learn more on EAPCI and its activities on: www.escardio.org/eapci

Volume 12 Number 14
Feb 20, 2017
Volume 12 Number 14
View full issue

Suggested by Cory

Viewpoint

Feb 16, 2026
PCR: a new era dawns
Prendergast B
free

Editorial

10.4244/EIJ-D-25-01330 Feb 16, 2026
Aspirin discontinuation after ACS: timing the transition to ticagrelor monotherapy
Gragnano F and Calabrò P
free

Editorial

10.4244/EIJ-D-25-01331 Feb 16, 2026
Will the dream of "leave nothing behind" remain a utopia if we forget to optimise the systemic medical therapy?
Wykrzykowska J and Kraak R
free

State-of-the-Art

10.4244/EIJ-D-25-00598 Feb 16, 2026
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima A et al
free

Original Research

10.4244/EIJ-D-25-00618 Feb 16, 2026
Hertz contact intravascular lithotripsy for calcified coronary artery disease: the PINNACLE-I trial
Verheye S et al
open access

Flashlight

10.4244/EIJ-D-25-00431 Feb 16, 2026
A novel spacer for transcatheter treatment of tricuspid regurgitation
Barbieri F et al
open access
Chat with Cory
Hello , I'm Cory and I will do my best to answer your questions about this article. Please remember that this is an experimental feature, and that I'm still learning.
Can you provide a summary of the key findings in this article?
Can you extract and explain the primary hypothesis or research question addressed in this article?
What are the potential clinical applications or implications of the results presented in this paper?
How does this research contribute to our current understanding of cardiovascular disease management?
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved